Treatment of Col4a3−/− mice with anti-miR 21 that directly targets Mpv17l in kidney increases lifespan and protects Col4a3−/− mice from kidney disease progression by preventing miR-21-mediated suppression of the PPARα fatty acid metabolism and mitochondrial biogenesis pathways and inhibition of mitochondrial ROS generation in the kidney [100]. This evidence concerns the gene COL4A3 and kidney disorder.